Here are some news/notes from a day in MedCity, Minnesota:
Mayo Clinic has ended cardiology services at its office at Dubai Healthcare City in Dubai, mostly because of economic troubles in the once-booming city in the United Arab Emirates, according to the Post-Bulletin in Rochester.
St. Cloud Hospital hopes its $240 million expansion and renovation project will take health care safety to a new level, according to Finance & Commerce in Minneapolis.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Medical devices giant Medtronic Inc. will go before a Food & Drug Administration panel in early March to seek pre-market approval for its deep-brain stimulator for epilepsy, according to MassDevice.
If a final health bill passes — and that’s a big if — it’s likely to include a payment formula that would reward efficient, high-quality providers like Mayo Clinic, according to the Star Tribune in Minneapolis. But Mayo’s victory has come at a price. With some $250 billion in annual Medicare hospital spending at stake, the new payment formula has kicked up a huge fight between potential winners and losers. It has even raised the question: Is Mayo as good as it claims?
A lawsuit filed in Los Angeles Superior Court claims Medtronic Inc. pays doctors to promote a medical device for off-label uses, and the InfuseBone Graft is “unreasonably dangerous” because its active ingredient can travel from the implant site to the esophagus or trachea, turning soft tissue into bone, according to Courthouse News Service.
